Human Tetanus Immunoglobulin Bio Products Laboratory (Human Tetanus Immunoglobulin)

Human Tetanus Immunoglobulin is indicated for specific clinical situations where rapid protection against tetanus is required.

• Prevention of tetanus in persons with incomplete or unknown primary tetanus immunization who have sustained a wound at risk for Clostridium tetani exposure.
• Post‑exposure prophylaxis for individuals with a dirty or contaminated wound when active immunization cannot be administered promptly.
• Adjunctive therapy for patients who have been exposed to tetanus toxin and require immediate neutralization while awaiting active vaccine response.
• Use in emergency settings when tetanus vaccination status is uncertain and rapid passive immunity is needed.

• Human tetanus immunoglobulin consists of purified IgG antibodies derived from pooled human plasma that have high affinity for tetanus toxin. After intramuscular injection, the antibodies circulate systemically and bind to free tetanus neurotoxin, forming immune complexes that prevent the toxin from attaching to neuronal membranes and entering nerve cells. This neutralization blocks the toxin’s enzymatic activity, thereby averting the development of tetanus symptoms.

Adverse reactions to human tetanus immunoglobulin are generally infrequent but may occur following intramuscular administration.

Common

• Injection site pain, redness, or swelling that usually resolves within a few days.
• Low‑grade fever occurring within 24 hours after administration.
• Headache that may be mild to moderate in intensity.
• Nausea or mild gastrointestinal discomfort such as stomach upset.

Serious

• Anaphylactic or severe allergic reaction, including difficulty breathing, hives, or swelling of the face and throat.
• Serum‑sickness–like illness presenting with fever, rash, joint pain, and lymph node enlargement.
• Acute hemolysis manifested by sudden drop in hemoglobin, dark urine, and fatigue.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, though extremely rare.

Before using human tetanus immunoglobulin, healthcare providers should assess patient history and consider specific safety factors.

• Verify that the patient has not received tetanus immune globulin within the previous three months.
• Assess for hypersensitivity to human immunoglobulins or any formulation component.
• Use caution in individuals with a history of severe allergic reactions or anaphylaxis.
• Evaluate renal or hepatic impairment, as altered clearance may affect tolerability.
• Consider the patient’s immunization record; active tetanus vaccination should follow passive immunization when appropriate.
• Avoid use in patients with uncontrolled bleeding disorders unless benefits outweigh risks.

Human tetanus immunoglobulin may interact with other agents; awareness of potential interactions helps ensure safe administration.

Avoid

• Simultaneous administration with live tetanus vaccine, as passive antibodies can neutralize the vaccine antigen.
• Concurrent use with other immunoglobulin products that could increase the risk of hyperviscosity.

Use with caution

• Concomitant anticoagulant therapy, because intramuscular injection may increase bleeding risk.
• Administration with other blood‑derived products, requiring monitoring for additive immune reactions.
• Use in patients receiving immunosuppressive agents, as the clinical benefit may be altered.
• Co‑administration with vaccines other than tetanus, ensuring appropriate timing to avoid interference.